Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
JNJ Johnson & Johnson
168.230-0.660-0.39%
Close
01/27 16:00 ET
168.100-0.130-0.08%
Post Mkt Price 01/27 19:50 ET
High
168.866
Open
168.540
Turnover
1.02B
Low
167.770
Pre Close
168.890
Volume
6.06M
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Johnson & Johnson (NYSE:JNJ) Stock Position Reduced by Fiera Capital Corp
Fiera Capital Corp cut its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.6% during the third quarter, according to its most recent disclosure with the SEC. The institutional inve
Tru Independence LLC Acquires 85 Shares of Johnson & Johnson (NYSE:JNJ)
tru Independence LLC raised its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund
The Use of Artificial Intelligence in Medical Devices and Drug Development
Johnson & Johnson Stock Outperforms Competitors Despite Losses On The Day
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Johnson & Johnson (JNJ) sank 0.39% to $168.23 Friday, on what proved to be an all-around gr
Johnson & Johnson's Janssen Says Carvykti Meets Target in Late-Stage Blood Cancer Trial
12:54 PM EST, 01/27/2023 (MT Newswires) -- Johnson & Johnson (JNJ) unit Janssen Pharmaceutical said Friday its phase 3 trial assessing Carvykti against standard of care treatments for patients with re
BTIG Sees Legend Commercializing Carvykti in Earlier Lines After Study Hits Goal
Piper Keeps $78 Target on Legend Biotech After Carvykti Trial Hits
Valmark Advisers Inc. Acquires 234 Shares of Johnson & Johnson (NYSE:JNJ)
Valmark Advisers Inc. grew its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exch
JNJ/ Legend CAR-T Therapy Succeeds in Phase 3 Multiple Myeloma Trial
Johnson & Johnson Unit Withdraws European Application for Imbruvica Drug Combination to Treat Mantle Cell Lymphoma
08:52 AM EST, 01/27/2023 (MT Newswires) -- Johnson & Johnson's (JNJ) Janssen-Cilag International NV unit has withdrawn its European marketing application to extend the use of Imbruvica combined with b
Company Overview
More
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
CEO： Mr. Joaquin Duato
Market： NYSE
Listing Date： 09/25/1944
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet